Factor XIII - CSL Behring

Drug Profile

Factor XIII - CSL Behring

Alternative Names: Blood coagulation factor XIII - CSL Behring; Coagulation factor XIII - CSL Behring; Corifact; Fibrin stabilising factor - CSL Behring; Fibrogammin-P

Latest Information Update: 19 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CSL Behring
  • Developer CSL Behring; University College London
  • Class Antihaemorrhagics; Blood coagulation factors
  • Mechanism of Action Factor XIII stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Factor XIII deficiency
  • New Molecular Entity No

Highest Development Phases

  • Marketed Factor XIII deficiency; Surgical blood loss
  • Phase II Systemic scleroderma

Most Recent Events

  • 28 Feb 2013 Launched for Surgical blood loss in USA (IV)
  • 28 Feb 2013 Registered for Surgical blood loss in USA (IV)
  • 31 Aug 2011 CSL Behring completes a phase III trial in Factor XIII deficiency in USA (NCT00945906)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top